Goiter medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(20 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Goiter}}
{{Goiter}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}{{ARK}} {{MJ}}


==Overview==
==Overview==
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
Pharmacologic medical [[therapy]] for goiter involves normalizing [[thyroid hormone]] levels and treating the [[inflammation]]. Treatment regimen involves [[Lugol's iodine]], [[Antithyroid agents|antithyroid drugs]] and [[Beta blockers|β-adrenergic blockers]]. In some cases, [[radioactive iodine]] may be used to treat an overactive [[thyroid gland]].


OR
==Medical Therapy==
 
*[[Pharmacological|Pharmacologic]] medical [[therapy]] is recommended for [[patients]] with goiter. <ref name="Astwood1960">{{cite journal|last1=Astwood|first1=E. B.|title=Treatment of Goiter and Thyroid Nodules with Thyroid|journal=JAMA|volume=174|issue=5|year=1960|pages=459|issn=0098-7484|doi=10.1001/jama.1960.03030050001001}}</ref><ref name="pmid2709545">{{cite journal |vauthors=Sawin CT, Geller A, Hershman JM, Castelli W, Bacharach P |title=The aging thyroid. The use of thyroid hormone in older persons |journal=JAMA |volume=261 |issue=18 |pages=2653–5 |year=1989 |pmid=2709545 |doi= |url=}}</ref><ref name="Sawin1989">{{cite journal|last1=Sawin|first1=Clark T.|title=The Aging Thyroid|journal=JAMA|volume=261|issue=18|year=1989|pages=2653|issn=0098-7484|doi=10.1001/jama.1989.03420180077034}}</ref><ref name="pmid23008749">{{cite journal |vauthors=Führer D, Bockisch A, Schmid KW |title=Euthyroid goiter with and without nodules--diagnosis and treatment |journal=Dtsch Arztebl Int |volume=109 |issue=29-30 |pages=506–15; quiz 516 |year=2012 |pmid=23008749 |pmc=3441105 |doi=10.3238/arztebl.2012.0506 |url=}}</ref><ref name="BaskinCobin2002">{{cite journal|last1=Baskin|first1=H. Jack|last2=Cobin|first2=Rhoda H.|last3=Duick|first3=Daniel S.|last4=Gharib|first4=Hossein|last5=Guttler|first5=Richard B.|last6=Kaplan|first6=Michael M.|last7=Segal|first7=Robert L.|last8=Garber|first8=Jeffrey R.|last9=Hamilton|first9=Carlos R.|last10=Handelsman|first10=Yehuda|last11=Hellman|first11=Richard|last12=Kukora|first12=John S.|last13=Levy|first13=Philip|last14=Palumbo|first14=Pasquale J.|last15=Petak|first15=Steven M.|last16=Rettinger|first16=Herbert I.|last17=Rodbard|first17=Helena W.|last18=Service|first18=F. John|last19=Shankar|first19=Talla P.|last20=Stoffer|first20=Sheldon S.|last21=Tourtelot|first21=John B.|title=AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM|journal=Endocrine Practice|volume=8|issue=6|year=2002|pages=457–469|issn=1530-891X|doi=10.4158/1934-2403-8.6.457}}</ref><ref name="WescheTiel-v Buul2001">{{cite journal|last1=Wesche|first1=Maria F. T.|last2=Tiel-v Buul|first2=Monique M. C.|last3=Lips|first3=Paul|last4=Smits|first4=Nico J.|last5=Wiersinga|first5=Wilmar M.|title=A Randomized Trial Comparing Levothyroxine with Radioactive Iodine in the Treatment of Sporadic Nontoxic Goiter|journal=The Journal of Clinical Endocrinology & Metabolism|volume=86|issue=3|year=2001|pages=998–1005|issn=0021-972X|doi=10.1210/jcem.86.3.7244}}</ref><ref name="BonnemaBertelsen1999">{{cite journal|last1=Bonnema|first1=Steen J.|last2=Bertelsen|first2=Henrik|last3=Mortensen|first3=Jesper|last4=Andersen|first4=Peter B.|last5=Knudsen|first5=Dorthe U.|last6=Bastholt|first6=Lars|last7=Hegedüs|first7=Laszlo|title=The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function1|journal=The Journal of Clinical Endocrinology & Metabolism|volume=84|issue=10|year=1999|pages=3636–3641|issn=0021-972X|doi=10.1210/jcem.84.10.6052}}</ref><ref name="NygaardKnudsen1997">{{cite journal|last1=Nygaard|first1=Birte|last2=Knudsen|first2=Jens Helmer|last3=Hegedüs|first3=Laszlo|last4=Scient|first4=Annegrete Veje Cand|last5=Mølholm Hansen|first5=Jens Erik|title=Thyrotropin Receptor Antibodies and Graves’ Disease, a Side-Effect of131I Treatment in Patients with Nontoxic Goiter1|journal=The Journal of Clinical Endocrinology & Metabolism|volume=82|issue=9|year=1997|pages=2926–2930|issn=0021-972X|doi=10.1210/jcem.82.9.4227}}</ref><ref name="GreerAstwood1953">{{cite journal|last1=Greer|first1=Monte A.|last2=Astwood|first2=E. B.|title=TREATMENT OF SIMPLE GOITER WITH THYROID*|journal=The Journal of Clinical Endocrinology & Metabolism|volume=13|issue=11|year=1953|pages=1312–1331|issn=0021-972X|doi=10.1210/jcem-13-11-1312}}</ref><ref name="SquatritoVigneri1986">{{cite journal|last1=Squatrito|first1=S.|last2=Vigneri|first2=R.|last3=Rybello|first3=F.|last4=Ermans|first4=A. M.|last5=Polley|first5=R. D.|last6=Ingbar|first6=S. H.|title=Prevention and Treatment of Endemic Iodine-Deficiency Goiter by Iodination of a Municipal Water Supply*|journal=The Journal of Clinical Endocrinology & Metabolism|volume=63|issue=2|year=1986|pages=368–375|issn=0021-972X|doi=10.1210/jcem-63-2-368}}</ref><ref name="HegedüsBonnema2010">{{cite journal|last1=Hegedüs|first1=Laszlo|last2=Bonnema|first2=Steen J.|title=Approach to Management of the Patient with Primary or Secondary Intrathoracic Goiter|journal=The Journal of Clinical Endocrinology & Metabolism|volume=95|issue=12|year=2010|pages=5155–5162|issn=0021-972X|doi=10.1210/jc.2010-1638}}</ref><ref name="HainesKeating1948">{{cite journal|last1=Haines|first1=Samuel F.|last2=Keating|first2=F. Raymond|last3=Power|first3=Marschelle H.|last4=Williams|first4=Marvin M. D.|last5=Kelsey|first5=Mavis P.|title=THE USE OF RADIOIODINE IN THE TREATMENT OF EXOPHTHALMIC GOITER*|journal=The Journal of Clinical Endocrinology & Metabolism|volume=8|issue=10|year=1948|pages=813–825|issn=0021-972X|doi=10.1210/jcem-8-10-813}}</ref><ref name="Reveno1948">{{cite journal|last1=Reveno|first1=William S.|title=PROPYLTHIOURACIL IN THE TREATMENT OF TOXIC GOITER|journal=The Journal of Clinical Endocrinology & Metabolism|volume=8|issue=10|year=1948|pages=866–874|issn=0021-972X|doi=10.1210/jcem-8-10-866}}</ref><ref name="BrentaSchnitman2003">{{cite journal|last1=Brenta|first1=G.|last2=Schnitman|first2=M.|last3=Fretes|first3=O.|last4=Facco|first4=E.|last5=Gurfinkel|first5=M.|last6=Damilano|first6=S.|last7=Pacenza|first7=N.|last8=Blanco|first8=A.|last9=Gonzalez|first9=E.|last10=Pisarev|first10=M. A.|title=Comparative Efficacy and Side Effects of the Treatment of Euthyroid Goiter with Levo-Thyroxine or Triiodothyroacetic Acid|journal=The Journal of Clinical Endocrinology & Metabolism|volume=88|issue=11|year=2003|pages=5287–5292|issn=0021-972X|doi=10.1210/jc.2003-030095}}</ref>
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
 
OR
 
The majority of cases of [disease name] are self-limited and require only supportive care.


OR
==== Hypothyroidism: ====
*In cases of [[hypothyroidism]], [[thyroid hormone]] replacement with [[levothyroxine]] may help resolve [[symptoms]] of [[hypothyroidism]] and also help with the slow release of [[Thyroid-stimulating hormone|thyroid stimulating hormone]] ([[Thyroid-stimulating hormone|TSH]]) from [[pituitary]] which would result in the decrease in the size of the goiter.
*The drug used in the treatment of [[hypothyroidism]] is:
*#[[Levothyroxine]]:
*#*Lifelong synthetic [[levothyroxine]] (L-[[T4]]) is used to treat the hypothyroidism.
*#*Main goals of levothyroxine replacement therapy are:
*#**Resolution of the [[hypothyroid]] symptoms and signs including biological and physiologic markers of [[hypothyroidism]],
*#**Normalization of serum [[thyrotropin]] with improvement in thyroid hormone concentrations,
*#**To avoid overtreatment (iatrogenic thyrotoxicosis).
*#*Side effects include [[atrial fibrillation]] and [[osteoporosis]]. Drug Regimen:
**[[Levothyroxine (oral)|Synthetic levothyroxine]] (L-[[T4]]) 1.6–1.8 μg/kg of body weight per day orally.


[Disease name] is a medical emergency and requires prompt treatment.
==== Hyperthyroidism: ====
*In [[hyperthyroidism]], treatment targeted at normalizing [[thyroid hormone]] levels is considered.
*In cases of [[inflammation]] of [[thyroid gland]], medication to treat the [[inflammation]] are generally prescribed. For goiters associated with [[hyperthyroidism]], you may need [[medications]] to normalize [[thyroid hormone]] levels.
*'''[[Radioactive Iodine]]:''' In some cases, [[radioactive iodine]] may be used to treat an overactive [[thyroid gland]]. [[Radioactive iodine]] is prescribed as an [[oral]] medication which helps destroy thyroid cells resulting in the decreasing the size of the goiter. This therapy may also lead to under-activity of the [[thyroid gland]].
*[[Lugol's iodine]]:
**Decreases [[thyroid hormone]] synthesis,
**Decreases [[vascularity]].
*[[Antithyroid drugs]] such as [[carbimazole]], [[methimazole]]:
**Used to restore the patient to a [[euthyroid]] state
*[[β-adrenergic blockers]] such as [[propranolol]]:
**Lowers [[tachycardia]] and [[palpitations]],
**Used to restore the patient to a [[euthyroid]] state,
**It also decreases [[vascularity]].


OR
*The following table summarizes the medical therapy and surgical option for treatment.


The mainstay of treatment for [disease name] is [therapy].


OR
<SMALL>
 
{| class="wikitable"
The optimal therapy for [malignancy name] depends on the stage at diagnosis.
!Treatment
!Mechanism
!Route of administration
!Advantages
!Disadvantages
!Special considerations
|-
|Beta-blockers
|
* Block β-adrenergic receptors;


OR
* propranolol may block conversion of T4 to T3
|Oral; may be administered
intravenously in acute


[Therapy] is recommended among all patients who develop [disease name].
cases
|Ameliorates sweating, anxiety, tremulousness, palpitations, and tachycardia
|
* Does not influence course of disease


OR
* Use cautiously in patients with asthma, CHF , bradyarrhythmias or Raynaud’s phenomenon
|
* Use cardioselective beta-blockers, especially in patients with COPD
* Use calcium-channel blockers as alternative
|-
|Antithyroid drugs ([[methimazole]],
[[carbimazole]],
and [[propylthiouracil]])
|
* Methimazole, carbimazole, and propylthiouracil block thyroid peroxidase and thyroid hormone synthesis


Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
* propylthiouracil also blocks conversion of thyroxine to triiodothyronine
|Given as either a single, high fixed dose (e.g., 10–30 mg of methimazole or 200–600 mg of propylthiouracil daily)


OR
and adjusted as euthyroidism is achieved or combined with thyroxine to prevent hypothyroidism (“block–replace” regimen)
 
|
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
* Outpatient therapy
 
* Low risk of hypothyroidism
OR
* No radiation hazard or surgical risk
 
* Remission rate 40–50%
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
|
 
* High recurrence rate
OR
* Frequent  testing required unless block-replacement therapy is used
 
* Minor side effects in ≤5% of patients (rash, urticaria, arthralgia, fever, nausea, abnormalities of taste and smell)
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
|Major side effect usually within first 3 mo of therapy
 
* Agranulocytosis in <0.2% of patients
==Medical Therapy==
* Hepatotoxicity in ≤0.1%
*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
* Cholestasis for the thionamides and hepatocellular necrosis for propylthiouracil
*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
* Antineutrophil cytoplasmic antibody–associated vasculitis in ≤0.1% of patients
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
|-
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
|[[Iodine-131|Radioactive iodine]]
===Disease Name===


* '''1 Stage 1 - Name of stage'''
(iodine-131)
** 1.1 '''Specific Organ system involved 1'''
|
*** 1.1.1 '''Adult'''
* Irradiation causes thyroid cell damage and cell death
**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' 
|Oral; activity either fixed (e.g., 15 mCi [555 MBq]) or calculated on the basis of goiter size and uptake and turnover investigations
**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
|
**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
* Normally outpatient procedure
**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
* Definitive therapy
**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
* Low cost
**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
* Few side effects
*** 1.1.2 '''Pediatric'''
* Effectively reduces goiter size
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
|
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose) 
* Potential radiation hazards
***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
* Adherence to a country’s particular radiation regulations
***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
* Radiation thyroiditis
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
* Decreasing efficacy with increasing goiter size
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
* Eventual hypothyroidism in most patients
****1.1.2.2 (Specific population e.g. ''''''children < 8 years of age'''''')
|
***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
* Should not be used in patients with active thyroid ophthalmopathy
***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
* Contraindicated in women who are pregnant or breast-feeding and for 6 wk after breast-feeding has stopped
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose) 
|-
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
|Thyroidectomy
** 2.1 '''Specific Organ system involved 2'''
|Most or all thyroid tissue is removed surgically
*** 2.1.1 '''Adult'''
| -----
**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
|
*** 2.1.2  '''Pediatric'''
* Rapid euthyroidism
**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
* Recurrence extremely rare


* 2 '''Stage 2 - Name of stage'''
* No radiation hazard,
** 2.1 '''Specific Organ system involved 1 '''
* Definitive histologic results
**: '''Note (1):'''
* Rapid relief of pressure symptoms
**: '''Note (2)''':
|
**: '''Note (3):'''
* Most expensive therapy
*** 2.1.1 '''Adult'''
* Hypothyroidism is the aim
**** Parenteral regimen
* Risks associated with surgery and anesthesiology
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
* Minor complications in 1–2% of patients (bleeding, infection, scarring),  
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
* Major complications in 1–4% (hypoparathyroidism, recurrent laryngeal-nerve damage)
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
|
**** Oral regimen
* Does not influence course of Graves’ ophthalmopathy during pregnancy
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
* Is best performed during the second trimester
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
|}
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
</SMALL>
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.1.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) ''''''(Contraindications/specific instructions)''''''
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
**: '''Note (1):'''
**: '''Note (2)''':
**: '''Note (3):'''
*** 2.2.1 '''Adult'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
**** Oral regimen
***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
*** 2.2.2 '''Pediatric'''
**** Parenteral regimen
***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
**** Oral regimen
***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)


==References==
==References==

Latest revision as of 19:51, 20 November 2017

Goiter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Goiter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goiter medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Goiter medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goiter medical therapy

CDC on Goiter medical therapy

Goiter medical therapy in the news

Blogs on Goiter medical therapy

Directions to Hospitals Treating Cushing’s disease

Risk calculators and risk factors for Goiter medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2] Mehrian Jafarizade, M.D [3]

Overview

Pharmacologic medical therapy for goiter involves normalizing thyroid hormone levels and treating the inflammation. Treatment regimen involves Lugol's iodine, antithyroid drugs and β-adrenergic blockers. In some cases, radioactive iodine may be used to treat an overactive thyroid gland.

Medical Therapy

Hypothyroidism:

Hyperthyroidism:

  • The following table summarizes the medical therapy and surgical option for treatment.


Treatment Mechanism Route of administration Advantages Disadvantages Special considerations
Beta-blockers
  • Block β-adrenergic receptors;
  • propranolol may block conversion of T4 to T3
 Oral; may be administered

intravenously in acute

cases

Ameliorates sweating, anxiety, tremulousness, palpitations, and tachycardia
  • Does not influence course of disease
  • Use cautiously in patients with asthma, CHF , bradyarrhythmias or Raynaud’s phenomenon
  • Use cardioselective beta-blockers, especially in patients with COPD
  • Use calcium-channel blockers as alternative
Antithyroid drugs (methimazole,

carbimazole, and propylthiouracil)

  • Methimazole, carbimazole, and propylthiouracil block thyroid peroxidase and thyroid hormone synthesis
  • propylthiouracil also blocks conversion of thyroxine to triiodothyronine
 Given as either a single, high fixed dose (e.g., 10–30 mg of methimazole or 200–600 mg of propylthiouracil daily)

and adjusted as euthyroidism is achieved or combined with thyroxine to prevent hypothyroidism (“block–replace” regimen)

  • Outpatient therapy
  • Low risk of hypothyroidism
  • No radiation hazard or surgical risk
  • Remission rate 40–50%
  • High recurrence rate
  • Frequent testing required unless block-replacement therapy is used
  • Minor side effects in ≤5% of patients (rash, urticaria, arthralgia, fever, nausea, abnormalities of taste and smell)
 Major side effect usually within first 3 mo of therapy
  • Agranulocytosis in <0.2% of patients
  • Hepatotoxicity in ≤0.1%
  • Cholestasis for the thionamides and hepatocellular necrosis for propylthiouracil
  • Antineutrophil cytoplasmic antibody–associated vasculitis in ≤0.1% of patients
Radioactive iodine

(iodine-131)

  • Irradiation causes thyroid cell damage and cell death
 Oral; activity either fixed (e.g., 15 mCi [555 MBq]) or calculated on the basis of goiter size and uptake and turnover investigations
  • Normally outpatient procedure
  • Definitive therapy
  • Low cost
  • Few side effects
  • Effectively reduces goiter size
  • Potential radiation hazards
  • Adherence to a country’s particular radiation regulations
  • Radiation thyroiditis
  • Decreasing efficacy with increasing goiter size
  • Eventual hypothyroidism in most patients
  • Should not be used in patients with active thyroid ophthalmopathy
  • Contraindicated in women who are pregnant or breast-feeding and for 6 wk after breast-feeding has stopped
Thyroidectomy Most or all thyroid tissue is removed surgically -----
  • Rapid euthyroidism
  • Recurrence extremely rare
  • No radiation hazard,
  • Definitive histologic results
  • Rapid relief of pressure symptoms
  • Most expensive therapy
  • Hypothyroidism is the aim
  • Risks associated with surgery and anesthesiology
  • Minor complications in 1–2% of patients (bleeding, infection, scarring),
  • Major complications in 1–4% (hypoparathyroidism, recurrent laryngeal-nerve damage)
  • Does not influence course of Graves’ ophthalmopathy during pregnancy
  • Is best performed during the second trimester

References

  1. ↑ Astwood, E. B. (1960). "Treatment of Goiter and Thyroid Nodules with Thyroid". JAMA. 174 (5): 459. doi:10.1001/jama.1960.03030050001001. ISSN 0098-7484.
  2. ↑ Sawin CT, Geller A, Hershman JM, Castelli W, Bacharach P (1989). "The aging thyroid. The use of thyroid hormone in older persons". JAMA. 261 (18): 2653–5. PMID 2709545.
  3. ↑ Sawin, Clark T. (1989). "The Aging Thyroid". JAMA. 261 (18): 2653. doi:10.1001/jama.1989.03420180077034. ISSN 0098-7484.
  4. ↑ Führer D, Bockisch A, Schmid KW (2012). "Euthyroid goiter with and without nodules--diagnosis and treatment". Dtsch Arztebl Int. 109 (29–30): 506–15, quiz 516. doi:10.3238/arztebl.2012.0506. PMC 3441105. PMID 23008749.
  5. ↑ Baskin, H. Jack; Cobin, Rhoda H.; Duick, Daniel S.; Gharib, Hossein; Guttler, Richard B.; Kaplan, Michael M.; Segal, Robert L.; Garber, Jeffrey R.; Hamilton, Carlos R.; Handelsman, Yehuda; Hellman, Richard; Kukora, John S.; Levy, Philip; Palumbo, Pasquale J.; Petak, Steven M.; Rettinger, Herbert I.; Rodbard, Helena W.; Service, F. John; Shankar, Talla P.; Stoffer, Sheldon S.; Tourtelot, John B. (2002). "AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM". Endocrine Practice. 8 (6): 457–469. doi:10.4158/1934-2403-8.6.457. ISSN 1530-891X.
  6. ↑ Wesche, Maria F. T.; Tiel-v Buul, Monique M. C.; Lips, Paul; Smits, Nico J.; Wiersinga, Wilmar M. (2001). "A Randomized Trial Comparing Levothyroxine with Radioactive Iodine in the Treatment of Sporadic Nontoxic Goiter". The Journal of Clinical Endocrinology & Metabolism. 86 (3): 998–1005. doi:10.1210/jcem.86.3.7244. ISSN 0021-972X.
  7. ↑ Bonnema, Steen J.; Bertelsen, Henrik; Mortensen, Jesper; Andersen, Peter B.; Knudsen, Dorthe U.; Bastholt, Lars; Hegedüs, Laszlo (1999). "The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function1". The Journal of Clinical Endocrinology & Metabolism. 84 (10): 3636–3641. doi:10.1210/jcem.84.10.6052. ISSN 0021-972X.
  8. ↑ Nygaard, Birte; Knudsen, Jens Helmer; Hegedüs, Laszlo; Scient, Annegrete Veje Cand; Mølholm Hansen, Jens Erik (1997). "Thyrotropin Receptor Antibodies and Graves' Disease, a Side-Effect of131I Treatment in Patients with Nontoxic Goiter1". The Journal of Clinical Endocrinology & Metabolism. 82 (9): 2926–2930. doi:10.1210/jcem.82.9.4227. ISSN 0021-972X.
  9. ↑ Greer, Monte A.; Astwood, E. B. (1953). "TREATMENT OF SIMPLE GOITER WITH THYROID*". The Journal of Clinical Endocrinology & Metabolism. 13 (11): 1312–1331. doi:10.1210/jcem-13-11-1312. ISSN 0021-972X.
  10. ↑ Squatrito, S.; Vigneri, R.; Rybello, F.; Ermans, A. M.; Polley, R. D.; Ingbar, S. H. (1986). "Prevention and Treatment of Endemic Iodine-Deficiency Goiter by Iodination of a Municipal Water Supply*". The Journal of Clinical Endocrinology & Metabolism. 63 (2): 368–375. doi:10.1210/jcem-63-2-368. ISSN 0021-972X.
  11. ↑ Hegedüs, Laszlo; Bonnema, Steen J. (2010). "Approach to Management of the Patient with Primary or Secondary Intrathoracic Goiter". The Journal of Clinical Endocrinology & Metabolism. 95 (12): 5155–5162. doi:10.1210/jc.2010-1638. ISSN 0021-972X.
  12. ↑ Haines, Samuel F.; Keating, F. Raymond; Power, Marschelle H.; Williams, Marvin M. D.; Kelsey, Mavis P. (1948). "THE USE OF RADIOIODINE IN THE TREATMENT OF EXOPHTHALMIC GOITER*". The Journal of Clinical Endocrinology & Metabolism. 8 (10): 813–825. doi:10.1210/jcem-8-10-813. ISSN 0021-972X.
  13. ↑ Reveno, William S. (1948). "PROPYLTHIOURACIL IN THE TREATMENT OF TOXIC GOITER". The Journal of Clinical Endocrinology & Metabolism. 8 (10): 866–874. doi:10.1210/jcem-8-10-866. ISSN 0021-972X.
  14. ↑ Brenta, G.; Schnitman, M.; Fretes, O.; Facco, E.; Gurfinkel, M.; Damilano, S.; Pacenza, N.; Blanco, A.; Gonzalez, E.; Pisarev, M. A. (2003). "Comparative Efficacy and Side Effects of the Treatment of Euthyroid Goiter with Levo-Thyroxine or Triiodothyroacetic Acid". The Journal of Clinical Endocrinology & Metabolism. 88 (11): 5287–5292. doi:10.1210/jc.2003-030095. ISSN 0021-972X.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Goiter_medical_therapy&oldid=1391132"